MAPT and amyloidosis: However, the data available to date suggest that baseline tau PET may predict the magnitude of clinical benefit associated with amyloid clearance by monoclonal antibodies as it appears that amyloid clearance appears to be more beneficial in individuals with earlier stages of tau progression according to PET.